Acasti Pharma, Inc. - (ACST): Price and Financial Metrics

Acasti Pharma, Inc. - (ACST): $2.19

0.02 (+0.92%)

POWR Rating

Component Grades














  • ACST scores best on the Sentiment dimension, with a Sentiment rank ahead of 77.61% of US stocks.
  • ACST's strongest trending metric is Momentum; it's been moving down over the last 33 weeks.
  • ACST's current lowest rank is in the Quality metric (where it is better than 2.28% of US stocks).

ACST Stock Summary

  • With a price/sales ratio of 288.38, Acasti Pharma Inc has a higher such ratio than 98.39% of stocks in our set.
  • In terms of volatility of its share price, ACST is more volatile than 99.45% of stocks we're observing.
  • Acasti Pharma Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -102.36%, greater than the shareholder yield of just 2% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Acasti Pharma Inc, a group of peers worth examining would be CBAT, LIVN, CHNG, RFL, and KERN.
  • ACST's SEC filings can be seen here. And to visit Acasti Pharma Inc's official web site, go to

ACST Valuation Summary

  • In comparison to the median Healthcare stock, ACST's price/sales ratio is 9231.58% higher, now standing at 354.6.
  • Over the past 116 months, ACST's EV/EBIT ratio has gone up 226.4.
  • Over the past 116 months, ACST's EV/EBIT ratio has gone up 226.4.

Below are key valuation metrics over time for ACST.

Stock Date P/S P/B P/E EV/EBIT
ACST 2021-08-31 354.6 1.3 -3.8 -1.9
ACST 2021-08-30 426.5 1.6 -4.6 -2.9
ACST 2021-08-27 442.9 1.6 -4.8 -3.1
ACST 2021-08-26 461.7 1.7 -5.0 -3.3
ACST 2021-08-25 499.5 1.8 -5.4 -3.8
ACST 2021-08-24 483.7 1.8 -5.2 -3.6

ACST's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ACST has a Quality Grade of F, ranking ahead of 2.28% of graded US stocks.
  • ACST's asset turnover comes in at 0.005 -- ranking 409th of 677 Pharmaceutical Products stocks.
  • FSTX, APLS, and AUPH are the stocks whose asset turnover ratios are most correlated with ACST.

The table below shows ACST's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.005 0.612 -2.164
2021-03-31 0.006 0.612 -7.694
2020-12-31 0.004 0.556 15.764
2020-09-30 0.000 NA 8.069
2020-06-30 0.000 NA 5.574
2020-03-31 0.000 NA 5.798

ACST Price Target

For more insight on analysts targets of ACST, see our ACST price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $1.99 Average Broker Recommendation 2 (Hold)

ACST Stock Price Chart Interactive Chart >

Price chart for ACST

ACST Price/Volume Stats

Current price $2.19 52-week high $9.76
Prev. close $2.17 52-week low $1.37
Day low $2.14 Volume 416,900
Day high $2.22 Avg. volume 2,742,672
50-day MA $3.38 Dividend yield N/A
200-day MA $4.25 Market Cap 57.05M

Acasti Pharma, Inc. - (ACST) Company Bio

Acasti Pharma Inc operates as pharmaceutical company. The Company develops drugs for cardiovascular diseases. Acasti offers omega-3 phospholipids a major component of cell membranes.

ACST Latest News Stream

Event/Time News Detail
Loading, please wait...

ACST Latest Social Stream

Loading social stream, please wait...

View Full ACST Social Stream

Latest ACST News From Around the Web

Below are the latest news stories about Acasti Pharma Inc that investors may wish to consider to help them evaluate ACST as an investment opportunity.

Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21ˢᵗ

LAVAL, Québec, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that it will be presenting at the Oppenheimer Fall Healthcare Summit being held virtually September 20-23, 2021. Jan D’Alvise, President and Chief Executive Officer of Acasti Pharma, is scheduled to present on Tuesday, September 21, 2021 at 2:05 PM Eastern Time. Management will also be participating in one-on-one meetings with qualified members of the i

Yahoo | September 14, 2021

Acasti Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

LAVAL, Québec, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today announced that Jan D’Alvise, President and Chief Executive Officer of Acasti Pharma, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021. Acasti’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 13, 2021, at 7:0

Yahoo | September 8, 2021

Why Shares of Acasti Pharma Slumped Tuesday

Acasti Pharma (NASDAQ: ACST) fell by more than 18% in Tuesday trading. The company said that it had closed its merger with Grace Therapeutics; former Acasti shareholders now own 59% of the combined company. The second -- and more concerning -- part of the announcement was that the company would perform an 8-1 reverse split at the start of trading on Aug. 31.

Yahoo | August 31, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

The weekend is officially over and that means it's time to jump back into investing with a look at Monday's biggest pre-market stock movers!

William White on InvestorPlace | August 30, 2021

Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split

LAVAL, Québec, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti”) (NASDAQ: ACST–TSX-V: ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. (“Grace”) via merger. The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases. Based on management’s current forecasts, Acasti expects to have enough cash on its balance sheet following the merger to provide at l

Yahoo | August 27, 2021

Read More 'ACST' Stories Here

ACST Price Returns

1-mo -33.72%
3-mo -44.13%
6-mo -58.62%
1-year 26.56%
3-year -51.72%
5-year -86.78%
YTD -15.77%
2020 -86.73%
2019 195.18%
2018 -11.70%
2017 -24.80%
2016 -50.98%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8854 seconds.